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The respiratory tract carries out the crucial function of gas exchange, which is necessary for life. The immune system that operates within the respiratory tract must therefore be compatible with this vital function and maintain open airways at all times. However, inhaled air is not always innocuous, as it contains microorganisms and environmental particles, some of which can cause respiratory disease if they reach an appropriate niche. These inhalants need to be eliminated quickly by the immune system, as failure to do so can lead to inflam matory responses, resulting in swelling that closes the airways or infection that can lead to severe pneumonia.
To control pathogens, the immune response within the respiratory tract follows an ordered, stepwise pro gramme in which distinct tiers of defence are engaged 1 . Local sensor cells first detect an invading micro organism. This detection event can trigger cellintrinsic defence responses in cells that contain the pathogen, can lead to the secretion of chemoattractants to recruit rapid responder cells such as neutrophils, and can alert lungresident lymphoid cells through the secretion of first-order cytokines (FIG. 1) . The tissueresident lym phocytes that respond to firstorder cytokines include innate lymphoid cells (ILCs), innatelike lymphocytes, natural killer (NK) cells and tissueresident memory T (T RM ) cells. These lymphocytes, in turn, respond to firstorder cytokine signals by producing second-order cytokines, which recruit and enhance the activation of effector cells that can eliminate the pathogens or expel foreign particles. At each stage of the process, effector mechanisms are also activated; these can potentially control the infection and thus prevent the activation of subsequent immune responses, limiting inflammatory damage. This stepwise programme of immune defence thereby ensures that the minimum necessary response to a microorganism is engaged. Although the specific sensors and effector mechanisms vary, this core tiered response applies to both type 1 immune responses and type 2 immune responses, as it represents an emerging pattern of immune regulation that is common to a wide range of pathogens.
A variety of internal and external influences alter the activation or regulation of these tiers, often with patho logical consequences. In particular, external environ mental factors, including temperature and pollutants, can change the efficacy of antimicrobial responses, as can internal factors such as lung disease, ageing and obesity. Indeed, people at the extreme ends of the age spectrum, as well as obese individuals, are more suscep tible to respiratory infections 2, 3 , and understanding how age and obesity alter immunological functions is vital for designing therapies that improve clinical outcomes in these atrisk populations.
This Review focuses on discussing the different sensor and effector mechanisms of cellular responses that are responsible for antimicrobial host defence in the conducting airways and lungs immediately after a microbial infection. We have divided our discussion into type 1 and type 2 immune responses to better explore the shared and distinct features of these immune response paradigms. Although respiratory immune responses often culminate in the priming of adaptive immune responses, this topic has been reviewed elsewhere 1, 4 and is not discussed here; instead, we focus on the early innate responses that occur within minutes to hours of respiratory challenge. We discuss how these responses 
First-order cytokines
A group of cytokines released from the cells that initially sense the presence of a pathogen. These cytokines primarily function to alert tissue-resident lymphoid cell populations in order to coordinate an appropriate immune response to the pathogen.
Innate lymphoid cells (ILCs) . A group of lymphoid cells that lack B and T cell receptors and are resident in a variety of different organs. They are a major source of second-order cytokines that maintain tissue homeostasis and promote effective microbial clearance.
Early local immune defences in the respiratory tract
Akiko Iwasaki 1, 2 , Ellen F. Foxman 1, 3 and Ryan D. Molony 1 Abstract | The respiratory immune response consists of multiple tiers of cellular responses that are engaged in a sequential manner in order to control infections. The stepwise engagement of effector functions with progressively increasing host fitness costs limits tissue damage. In addition, specific mechanisms are in place to promote disease tolerance in response to respiratory infections. Environmental factors, obesity and the ageing process can alter the efficiency and regulation of this tiered response, increasing pathology and mortality as a result.
In this Review, we describe the cell types that coordinate pathogen clearance and tissue repair through the serial secretion of cytokines, and discuss how the environment and comorbidity influence this response.
A group of cytokines released from tissue-resident lymphoid cells in response to signals from first-order cytokines. These cytokines recruit effector cells, and activate effector and tissue-repair functions to help resolve infections. are mediated by various cell types and cytokines, how internal and external factors disrupt the nature of these responses, and how pathology arises. Along the way, we highlight topics worthy of future investigation.
Type 1 immune responses

Constitutive airway defences
Airway epithelial cells (AECs) contribute to keeping air ways open by continually and actively defending against infection at its earliest stages, averting the need to recruit leukocytes for this task and preventing the accompany ing inflammatory response. In addition to wellknown roles in barrier defences, accumulating evidence shows that epithelial cells also suppress infection via cell intrinsic innate immune responses. Furthermore, airway cells function as the key sensors of infection that inform the tissueresident lymphocytes through the secretion of firstorder cytokines.
Airway diameter-dependent barrier defences. The res piratory system consists of the conducting airways of the upper respiratory tract (the nasal cavity, pharynx and lar ynx) and the lower respiratory tract (the trachea, bronchi and bronchioles), and the respiratory zone (alveoli). Four major cell types produce a physical and chemical barrier to infection of the airways: namely, ciliated cells, mucus secreting goblet cells, club cells, and basal cells, which, along with club cells, function as regional progenitor cells to replenish the other cell types 5, 6 . The proportion of each cell type, and the associated defence mechanisms, corre late with airway diameter (FIG. 2) . In the human respira tory tract, ciliated cells and mucus secreting goblet cells create the barrier defence in the larger airways, whereas the smaller airways contain fewer mucussecreting goblet cells and increased numbers of secretory cells. Within the alveoli, alveolar type 1 cells facilitate gas exchange, whereas alveo lar type 2 cells secrete pulmonary sur factant. Immune defences are coordinated in relation to airway size, as effective defences of the large airways, such as a thick mucus layer, can be harmful rather than help ful in small airways. This is evident in diseases such as asthma and chronic obstructive pulmonary disease, in which mucus cell metaplasia in small airways contributes to airway obstruction 7 . The relationship between epithelial composition and airway diameter needs to be taken into consideration when using animal models of respiratory infection; for example, in terms of epithelial composition, a mouse trachea is quite different from a human trachea but is similar to a human bronchiole 6, 8 (FIG. 2) .
Localized sensor responses
When a pathogen manages to enter the airway, its initial detection by sensor cells that are localized at the site of infection functions as the first tier of defence; the sensor cells promote innate immune responses to clear limited In addition, a two-tiered response can be engaged, in which sensor cells secrete first-order cytokines that act on tissue-resident lymphoid cell populations, which integrate these signals and release appropriate second-order cytokines. These cytokines, in turn, recruit and activate effector cells and effector functions that are specific to the pathogen type, and promote pathogen clearance and tissue repair. AREG, amphiregulin; IL, interleukin; ISG, IFN-stimulated gene; NK, natural killer; TGFβ, transforming growth factor-β; TSLP, thymic stromal lymphopoietin. 
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Goblet cells
Cells that produce airway mucins, the key components of the protective barrier that impedes pathogen entry into the airway epithelium. infections, and they release firstorder cytokines that activate local tissueresident lymphocytes (FIG. 1) . In this section, we describe how local sensor cells detect and respond to infectious agents. In the steady state, the respiratory mucosa maintains its quiescence in part through the function of alveolar macrophages. Alveolar macrophages reside in the airway space of the alveoli and within the mucus of the larger conducting airways. Recent work demonstrates that these tissueresident macrophages arise from yolk sac progeni tor cells that are distinct from haematopoietic stem cells, and that shows that circulating monocytes contribute minimally to the alveolar macrophage compartment in young mice 9, 10 . Alveolar macrophages constantly receive negative regulatory cues from AECs; these signals include CD200, transforming growth factorβ (TGFβ) and inter leukin10 (IL10), which prevent alveolar macrophage activation 11 . As such, in the steady state alveolar macro phages function to clear particulates, apoptotic cells and cellular debris from the airways in order to maintain homeostatic tissue function (FIG. 3a) . A subset of mouse alveolar macrophages form connexin 43mediated gap junctions with AECs, and even during lipopoly saccharide (LPS)induced inflammation, these cells use Ca 2+ dependent signalling to rapidly transmit immuno suppressive signals to local AECs and macrophages, which helps to constrain consequent inflammation 12 .
Club cells
Local sensor cells in type 1 immunity. Upon infec tion with viruses, bacteria, protozoa and fungi, type 1 immune responses are initiated by sensor cells, including AECs, alveolar macrophages and dendritic cells (DCs) (FIG. 3b) . These sensor cells express pattern recognition receptors (PRRs), including Tolllike receptors (TLRs), RIG-I-like receptors (RLRs), cytosolic DNA sensors and nucleotide oligomerization domain (NOD)like recep tors (NLRs). The specific combination of receptors, downstream signalling molecules and antimicrobial effector pathways that predominate in AECs differs from those found in other immune cell populations. For example, during the antiviral response of macrophages, DCs and plasmacytoid DCs (pDCs), the secretion of type I interferons (IFNs) predominates. In AECs, type III IFNs (the IFNλ family cytokines) are often secreted at higher levels than are type I IFNs, and the ability to respond to type III IFNs is also specific to epithelial cells, in both humans and mice 13, 14 . In diverse cell types, the engage ment of RLRs at peroxisomes, rather than at mitochon drial membranes, favours type III IFN induction 15 Figure 2 | Composition of the airway epithelium varies with airway diameter. The conducting airways include the air passages from the nasal cavity to the terminal bronchioles. The same major cell types form the airway epithelium lining in all these parts, but the relative proportion of each cell type varies with airway diameter, which is consistent with differences in functional requirements. This difference is also evident when comparing the cellular composition of the human conducting airways with that of mouse airways. Mucus-producing goblet cells are rare in the mouse airway epithelium beyond the upper airway; similarly, club cells are rare in human airways larger than the terminal bronchioles. The pie charts indicate the approximate proportions of the major cell types at different locations of the respiratory system (compiled from REFS 8, 152) . 
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Figure 3 | Single and two-tiered responses in type 1 immunity. a | In steady-state conditions in the airways, alveolar macrophage activation is suppressed by negative regulatory signals that are in part mediated by the CD200-CD200 receptor (CD200R) interaction and the recognition of transforming growth factor-β (TGFβ) presented by αvβ6 integrin on airway epithelial cells (AECs). b | During infection, disruption of these interactions due to death of AECs enables activation of alveolar macrophages. Recognition of viruses by pattern recognition receptors expressed by AECs leads to the secretion of interferon-λ (IFNλ), whereas recognition by endosomal Toll-like receptors (TLRs) in plasmacytoid DCs (pDCs), and cytosolic RIG-I-like receptors (RLRs) and DNA sensors in alveolar macrophages, leads to the production of IFNα and IFNβ. These IFNs induce an antiviral state in proximal AECs, inducing the expression of IFN-stimulated genes that help to constrain viral spread. c | TLRs expressed by alveolar macrophages and DCs that extend transepithelial processes enable the recognition of viral, fungal and bacterial molecules, and bacterial pathogens, in the airway; recognition of these molecules and pathogens leads to the production of first-order cytokines such as interleukin-12 (IL-12) and IL-23. Additional pathogen recognition via inflammasome activation leads to caspase 1-mediated activation and release of the first-order cytokine IL-1β. These first-order cytokines act on tissue-resident lymphoid populations of cytotoxic T lymphocytes to enhance the direct killing of infected cells, and they act on innate lymphoid cells (ILCs), natural killer (NK) cells, NKT cells and T cells to induce the production of appropriate second-order cytokines such as IFNγ, IL-17 and IL-22. These second-order cytokines, in turn, act on AECs to induce chemokine production, antimicrobial peptide release, and increased proliferation and/or tight junction formation to enhance airway integrity and constrain pathogen spread. Local and chemokine-recruited phagocytes, including neutrophils and monocytes, are also activated by IFNγ, which enhances their phagocytic capabilities and leads to enhanced pathogen lysis and clearance. IRF, IFN-regulatory factor; IFNAR, type I IFN receptor; IFNλR, IFNλ receptor; IL1R, IL-1 receptor; IL-10R, IL-10 receptor; IL-12R, IL-12 receptor; IL-23R, IL-23 receptor; iNOS, inducible nitric oxide synthase; NETs, neutrophil extracellular traps; NF-κB, nuclear factor-κB; NLR, nucleotide oligomerization domain (NOD)-like receptor; TGFβR, TGFβ receptor; T H , T helper; TNF, tumour necrosis factor. 
Plasmacytoid DCs
(pDCs). Specialized sensory cells that express Toll-like receptor 7 (TLR7) and TLR9, and rapidly produce large amounts of type I interferons in response to viral infection. 
Type I interferons
Alarmins
Constitutively expressed molecules that are released upon cell membrane rupture and alert the immune system.
AECs require the ATPdependent RNA helicase DHX29 as a coreceptor to sense certain cytosolic nucleic acids, whereas monocytederived THP1 cells do not 18 . Thus, AECs have the ability to function as specialized patho gen sensors, and they rely on specific regulatory cofac tors in the initiation of IFN responses, which act in an autocrine and paracrine fashion to limit viral spread within the AECs.
In addition to AECs, innate leukocytes -such as pDCs -that are present in lungs respond to viruses 19 . Antibodydepletion studies in mice show that pDCs are important for IFN production, viral clearance from the lung and limiting immunopathology 20, 21 . The type I and type III IFNs released by pDCs function as firstorder cytokines, inducing nearby cells to express IFNstimulated genes (ISGs), which have direct antiviral activities. IFNs also amplify subsequent local IFN pro duction if an infection is not rapidly controlled by the local antiviral response. Alveolar macrophages express a wide range of TLRs and cytosolic sensors, including retinoic acid inducible gene I (RIGI; also known as DDX58), melanoma differentiationassociated gene 5 (MDA5; also known as IFIH1), and cyclic GMP-AMP synthetase (cGAS) 22 . Upon infection, the negative regu latory signals, including CD200 and TGFβ, that normally constrain alveolar macrophage activation are lost (by virtue of epithelial cell death, for example), and alveo lar macrophages turn on their PRR signalling machinery 11 (FIG. 3b) . Alveolar macrophages are a major source of type I IFNs during viral infections of the lung 23 . Thus, type I IFNs mediate a singletiered immune response that does not rely on additional lymphoid cellmediated amplification or effector cell recruitment in order to control the infection (FIG. 3b) .
In addition to the singletiered response, twotiered immune responses are deployed. Infections by viruses, bacteria, fungi and protozoa are detected by sensor cells, including alveolar macrophages, AECs and DCs (FIG. 3c) . IFNs secreted by these sensor cells promote the induc tion of chemokines, including CCchemokine ligand 2 (CCL2), either from alveolar macrophages or from AECs in mice 23 , providing a means by which effector cells can be rapidly recruited to sites of infection. Alveolar macro phages also produce cytokines and chemokines -including IL6, tumour necrosis factor (TNF), IL12, IL23 and CCL3 -during infections in response to the activation of specific PRRs 24 (FIG. 3c) . There are multiple DC subsets in the lung in the steady state, and each sub set seems to have distinct roles in innate and adaptive immunity 1, 25 . Within the alveoli, and to a lesser extent in the conducting airways, DCs extend transepithelial processes that sample antigens that are not phagocytosed by alveolar macrophages 26, 27 . Upon pathogen detection, mouse lung DCs undergo TLRdependent secretion of firstorder cytokines, including IL12 and IL23, and migrate to the draining lymph nodes to prime T cell responses 28, 29 . This migration can depend on the com plement anaphylatoxins C3a and C5a 30 , and on activa tion of the NOD, LRR and pyrin domaincontaining 3 (NLRP3) inflammasome 31 , in addition to cytokine and chemokine signals. Inflammasome activation in response to virulence activity drives caspase 1 dependent release of IL1β and/or IL18 from PRRactivated macrophages and DCs 32, 33 , providing additional first order cytokines and signalling the presence of a virulent pathogen (FIG. 3c) . These first order cytokines act on tissueresident lymphoid cells, which produce secondorder cytokines, such as IFNγ, IL17 and IL22 (FIG. 3c) . The second order cytokines act on effector cells, which mediate the elimination of pathogens.
Local sensor cells in type 2 immunity. Type 2 immunity is activated in response to inhaled allergens or venoms, or invasion by multicellular parasites. In contrast to type 1 immunity, during which PRRs mediate the detection of pathogens, type 2 immunity is activated in response to the recognition of tissue damage caused by parasites and other features associated with pathogen invasion, such as the presence of proteases. Inhaled allergens, toxins and venoms elicit similar type 2 immune responses. Certain allergens exhibit TLR4dependent 34 or βglucan dependent 35 induction of firstorder cytokines in mouse models and in vitro analyses of human cells, respec tively, indicating that PRRs may detect certain aller gens. Sensors of allergens and helminths in the airways include AECs and mast cells, which together coordinate the initial production of firstorder cytokines, including thymic stromal lymphopoietin (TSLP), IL25, IL33 and IL1β (FIG. 4) .
Mast cells represent a unique class of sensor cell in that they are longlived resident cells that directly execute effector functions that eliminate helminths and aller gens from the airway through a singletiered immune response 1 (FIG. 4a) . Mast cells are activated directly in response to protease activity and via IgEmediated recognition of antigen, and they subsequently release effector molecules, including proteases, histamine and prostaglandins, which promote vasodilation and smooth muscle peristalsis 36 . Although such singletiered effector functions enable rapid expulsion of parasites from the airway, these functions can also lead to anaphylaxis and death in severe cases. In addition to these classical effec tor functions, mast cells can secrete firstorder cytokines, including IL25 (REF. 36 ), a process that is enhanced by human epitheliumderived TSLP 37 , which enables these cells to directly amplify type 2 immune responses by acting on tissueresident lymphocytes (FIG. 4b) .
Damage to the barrier integrity of the airway epi thelium leads to the release of alarmins. The best characterized airway alarmin is IL33, an IL1 family cytokine that is constitutively expressed and sequestered in the nuclei of AECs 38 . In the human airway, basal cells are the primary source of IL33, whereas in mice alveo lar type 2 cells are the predominant producers of IL33 (REF. 39 ), which emphasizes the differences in airway cell function that are observed between these species (FIG. 2) . IL33 is rapidly released from these cells upon exposure to allergens with protease activity 40, 41 , during necrotic cell death 42 or in response to mechanical stress 43 . In addition to the damagemediated release of constitu tively expressed alarmins, the expression and secretion of TSLP and IL25 are increased in AECs during type 2 inflammatory responses. Human AECs express and secrete TSLP in response to protease activity, which is partly sensed by proteaseactivated receptor 2 (PAR2) 44 . The expression and secretion of IL25 are also induced in AECs in response to allergen exposure 45, 46 . Together, these three firstorder cytokines -IL33, IL25 and TSLP -comprise the prototypical AEC response to allergens and parasitic infections. In mouse alveoli, alveo lar type 2 epithelial cells are the primary source of IL33 and TSLP during helminth infection, which is consistent with their role as cytokineproducing cells 47 .
More recently, the secretion of TGFβ from AECs was shown to be essential during mouse allergic responses by acting on local group 2 ILCs (ILC2s) to enhance their proliferation and cytokine secretion 48 (FIG. 4b) .
Lymphocyte responses
The second tier of respiratory immune defence is medi ated by terminally differentiated tissueresident lympho cytes, including ILCs; NK cells; innatelike lymphocytes such as NKT cells, mucosalassociated invariant T (MAIT) cells and epithelial γδ T cells; and antigen specific T RM cells. These cells function as intermedi ary controllers 49 , integrating the cytokine signals from local sensor cells and producing effector cytokines that can recruit effector cell subsets and elicit appropriate responses to clear pathogens. These cells reside within the respiratory tract at the time of infection and are thus distinct from effector lymphocytes that arrive as a con sequence of the activation of adaptive immunity several days later. Figure 4 | Single-tiered and two-tiered responses in type 2 immunity. a | Mast cells can be activated directly in response to certain protease activities and venom proteins homologous to mammalian mast cell-activating proteins, or through antigen-specific IgE-mediated signalling through Fcε receptors (FcεRs), whereupon they can form a single-tiered immune response to helminths and allergens. Activation leads to degranulation and the release of proteases, histamine and eicosanoids (including prostaglandins), as well as the production of certain effector cytokines. These molecules can directly initiate effector mechanisms that can promote worm expulsion but that are also associated with anaphylaxis in severe instances of allergy. b | Cell damage and protease activity resulting from helminth infection or exposure to allergens and venoms leads to the secretion and release of the first-order cytokines interleukin-25 (IL-25), thymic stromal lymphopoietin (TSLP), IL-33, IL-1α and transforming growth factor-β (TGFβ; which is presented by αvβ6 integrin) from sensory airway epithelial cells (AECs). These cytokines, in turn, act on tissue-resident lymphoid cells -including group 2 innate lymphoid cells (ILC2s), natural killer T (NKT) cells, T helper 2 (T H 2) cells and T H 9 cells -to drive the secretion of appropriate second-order cytokines, which act on mast cells, AECs, basophils and eosinophils to initiate effector mechanisms aimed at worm expulsion and tissue repair. First-order cytokines can also enhance the recruitment and activation of basophils and mast cells in order to appropriately calibrate the immune response. AREG, amphiregulin; TNF, tumour necrosis factor. 
Airway hyperresponsiveness
A pathological state in which narrowing of the conducting airways can be easily triggered. Airway hyperresponsiveness is a diagnostic feature of asthma and contributes to airway obstruction.
Tissue lymphocyte responses in type 1 immunity. ILCs are classified into three broad subsets on the basis of their effector cytokine production and differentiation, and all three populations are found in the lungs of healthy humans 50 . Group 1 ILCs (ILC1s) are associated with the production of effector cytokines associated with a T helper 1 (T H 1) response to viral and intracellular bac terial infections (FIG. 3c) . Group 3 ILCs (ILC3s) produce effector cytokines similar to those produced by T H 17 cells in response to extracellular bacteria and fungi (FIG. 3c) . Pulmonary IL17 production is dependent on IL23 sig nalling in mice 24 , and lung ILC3s are a main source of both IL17 and IL22 in response to IL23 (REF. 51 ).
NK cells are related to ILC1s. They are rapidly recruited to the lung and activated upon influenza virus infection 52 . NK cells are cytotoxic, and they recognize and lyse cells infected by viruses and intracellular bac teria. In addition to this cellmediated killing, NK cells are a major source of cytokines during certain respira tory infections. NK cell activation by IL12 leads to IFNγ production 53 , and in certain mouse models of infection NK cells also express IL23 receptor and are the domi nant producers of IL22 (REF. 54 ), which helps to restore the integrity of the epithelial barrier (FIG. 3c) .
Invariant NKT (iNKT) cells comprise multiple subsets of CD1drestricted lipidresponsive lympho cytes that function as major producers of secondorder cytokines. Studies in nonrespiratory organ systems have revealed a highly diverse set of cytokine responses from resident iNKT cell populations 55 , and the same is also true for pulmonary NKT cells. For example, mouse iNKT cells express the IL12 receptor, and undergo IL12dependent activation and IFNγ secretion in the lungs during bacterial infection 56 ; they can also secrete IL22 and IL17 in response to IL1β and IL23 during influenza virus infection 57 . Studies in mice have demonstrated that localized innatelike lymphocytes are also central to early and effective airway immunity. Lung γδ T cells secrete IL17 in response to IL1β and IL23 signalling 58 , and they are an early and prominent source of IL17 during Mycobacterium tuberculosis infection 59 . Conversely γδ T cells stimulated with IL1 and IL12 can produce IFNγ 60 , demonstrating that specific cytokine milieus elicit distinct effector cytokine responses from the same cell type.
During recall responses, lung T RM cells protect against infection 61 , and memory T H 1 and T H 17 cells are major sources of IFNγ and of IL17 and IL22, respectively. Of note, adaptive T cells that make up the local T RM cell popu lation represent a special case 1 because these cells need to undergo an additional step of antigenspecific expansion and differentiation before they are able to participate in the twotiered response within tissues.
There are clear functional similarities between these different lymphoid cell populations in terms of the types of secondorder cytokines that they can release. Even so, these cells retain nonredundant functions, such as the cytotoxic properties of NK cells, the ability of iNKT cells to respond to specific lipid species and the ability of T RM cells to respond to specific antigenic peptides. Hence, although each lymphoid cell type can respond to firstorder cytokines, some of these cell types can also respond to specific stimuli in order to mediate efficient antimicrobial defence.
Tissue lymphocyte responses in type 2 immunity. The firstorder cytokines released in response to helminth, venom or allergen detection direct the activation and function of tissueresident lymphocytes, including NKT cells, ILC2s and T RM cells, to produce appropri ate secondorder cytokines, such as IL4, IL5, IL13, amphiregulin (AREG) and IL9 (FIG. 4b) . DCs also respond to secondorder cytokines
.
ILC2s are found in the lung during steadystate con ditions in the absence of infection 62 . They proliferate and produce the canonical type 2 cytokines IL5 and IL13 during both helminth infections 63 and allergic responses 64 in mice. ILC2s constantly survey the airway epithelium and are highly responsive to AECderived cytokines, including IL25, IL33, TSLP and TGFβ 48, 63, 64 . Although both IL25 and IL33 can promote ILC2 proliferation, studies in mouse models of airway hyperresponsiveness suggest that IL33 is a more potent activator of these cells in vivo than is IL25 (REF 45) , and that IL25 activates a subset of ILC precursors that can be induced to differenti ate into ILC2s or ILC3s 65, 66 . TGFβ, but not IL33, enhances the basal migration rates of ILC2s, priming these cells to respond to additional chemotactic stimuli in the air ways 48 . Human ILC2s are also responsive to IL1α and IL1β, and IL1 signalling enhances the expression of the receptors for IL25, IL33 and TSLP; thus, IL1 signalling is important for priming and amplifying the responsive ness of ILC2s to firstorder cytokines in the context of an unresolved infection 67 . ILC2s have also been implicated as a major source of IL9 during lungstage helminth infections in mice, as autocrine IL9 signalling through IL9 receptor on ILC2s is necessary for sustained ILC2 function and epithelial repair 47, 68 . Together, these results suggest that the combination of AECderived firstorder cytokines in the lung specifies ILC2 function (FIG. 4b) .
Box 1 | Dendritic cells sense pathogens and cytokines in type 2 immunity
Dendritic cells (DCs) in the lung are highly responsive to first-order cytokines derived from airway epithelial cells (AECs) and second-order cytokines derived from lymphocytes. AEC-derived chemokines, such as CC-chemokine ligand 20 (CCL20), promote the migration of immature DCs to the airway 35 . Interleukin-33 (IL-33) directly promotes the activation of airway DCs and their migration to lymph nodes in the context of allergic airway inflammation 132 , and skin models of allergy suggest that epithelium-derived thymic stromal lymphopoietin (TSLP) can similarly activate DCs 133 . Airway DCs are also responsive to proximal signals from group 2 innate lymphoid cells (ILC2s), and ILC2-derived IL-13 induces DC migration to the draining lymph nodes 134 . Migration of CD11b + DCs and CD301b + DCs from the airways to the draining lymph nodes is essential for T helper 2 (T H 2) cell differentiation and type 2 immunity in the context of allergic inflammation 135 and lung helminth infections 136 , respectively. Whether AEC-derived cytokines are necessary or sufficient to initiate or enhance these DC responses remains to be determined; however, TSLP is dispensable for Nippostrongylus brasiliensis lung infections in vivo 137 , and helminth products may directly stimulate DC activation in this model. DCs constantly take up antigens from the airway, and certain common allergens interact with DC receptors such as Toll-like receptor 4 and DC-specific ICAM3-grabbing non-integrin 1 (DC-SIGN; also known as CD209) 138, 139 . Thus, activation of DCs in the context of type 2 immunity can occur as a consequence of both direct pathogen sensing and indirect activation by first-order and second-order cytokines. 70 and ozoneinduced airway hyperresponsiveness 71 . TSLP and IL33 similarly enhance NKT cell activation and cytokine secretion 72, 73 . In the mouse lung, Vα14expressing NKT cells reside in the intravascular space of the microvasculature, and they respond to the lipid antigen α galactosylceramide presented on CD1d by secreting IL4 and recruiting eosinophils 74 .
Neutrophil extracellular traps (NETs
In the context of recurrent allergen exposure or infec tion, adaptive T cell populations in the airways have a role distinct from that of ILC2s and NKT cells. Memory T H 2 cells can rapidly produce the effector cytokines IL4, IL5 and IL13 in response to allergens and hel minth infections owing to their exquisite sensitivity to the small amounts of antigen presented by local anti genpresenting cells (APCs). T H 9 cells rapidly produce IL9 in the lungs and have been implicated in allergic airway responses 75 . IL9 production is necessary for maximal allergeninduced mast cell accumulation and airway inflammation in mice 76, 77 . Recently, a distinct CD4 + T cell subset that secretes IL21 was identified in the mouse lung in the context of allergic airway inflammation, and this IL21 production supported the development of eosinophilia 78 (FIG. 4b) .
Adaptive T cells can also respond to firstorder cytokines independently of antigens. TSLP and IL25 enhance IL9 production by T H 9 cells 76, 79 , and TSLP, IL25 and IL33 promote effector cytokine produc tion by T H 2 cells 80, 81 , which demonstrates that first order cytokines secreted by AECs induce T cellmediated cytokine responses. In addition to its role in stimulating mast cell proliferation, IL9 has also been implicated in supporting ILC2 survival 68 , and IL21 indirectly supports ILC2 cytokine secretion 78 , suggesting that paracrine regu lation between different lymphocyte subsets helps to coordinate an optimal type 2 effector response (FIG. 4b) .
Effector responses
The signals from tissueresident lymphoid cell popula tions recruit and/or activate effector cell populations. These effector cells are the primary mode of pathogen clearance during serious infections when previous tiers of defence have failed.
Effector responses in type 1 immunity. Some effector responses are directly initiated by sensors, such as dur ing local control of viral infection within the airway epithelium by cellintrinsic defences or localized IFN responses, and as described for pDCs (FIG. 1) . Firstorder cytokines can also directly enhance effector responses; for example, cytotoxic T cells exhibit improved prim ing and cytotoxicity in response to DCderived IL12 (REF. 82 ). Other responses require additional input from secondorder cytokines that are secreted by tissue resident lymphoid cells; these cytokines stimulate effec tor cell types in the tissue to promote pathogen clearance.
IFNγ acts on tissue macro phages to enhance the phago cytosis of infected cells and infectious agents, whereas IL17 and IL22 act on AECs to induce the production of antimicrobial peptides 83 , strengthen tight junctions and induce proliferation and repair 54, 83 (FIG. 3c) . In addition to these responses, the recruitment of inflammatory cell types -particularly monocytes and neutrophils -is essential for the effective resolution of viral, bacterial and fungal respiratory infections.
Inflammatory monocytes are recruited to the lungs of infected mice in response to CCL2 and CCL7 (REFS 23, 84) , and have a central role in pathogen clear ance. Recruited monocytes can function as a major secondary source of cytokines, including type I IFNs, TNF and IL6, and their recruitment enhances sub sequent neutrophil recruitment to the lung 85, 86 . Once these inflammatory monocytes reach the site of infec tion they can differentiate into either macrophages or DCs 87 , reinfor cing sensor cell functions in the airway and increasing the local concentration of activated phago cytes and APCs 84 . Mouse monocytes can replenish alveo lar macrophage populations by first differentiating into CD11c + macrophages in the lung parenchyma and then migrating into the alveolar lumen 88 . Monocytederived macrophages and DCs also have direct innate roles in pathogen elimination; for example, monocytederived DCs produce TNF and/or inducible nitric oxide syn thase (iNOS) 87 , and can directly engulf spores during respiratory fungal infection 86 (FIG. 3c) .
Neutrophils arrive in the lung interstitium within minutes of highdose bacterial challenge, which is, in some cases, a response to the release of preexisting chemokine stores 89 . Pathogen sensing by AECs can also directly trigger their production of high levels of neutro phil chemoattractants. Thus, neutrophils can be directly recruited in a manner independent of lymphocyte mediated signal amplification (FIG. 1) . In addition, chemokine production by AECs can be amplified by the secondorder cytokines IL17 and IFNγ 90 , which enable additional neutrophil recruitment during the later stages of infection. The movement of neutrophils to sites of infection is dependent on their ability to secrete matrix metalloproteinase 9 (MMP9) 91 , which cleaves the colla gen of the extracellular matrix. Cytokines such as TNF directly enhance MMP9 secretion from mouse neutro phils 91 and thereby provide a regulatory checkpoint that prevents these cells from entering noninflamed tissues.
Activated neutrophils clear fungi, bacteria and viruses through both phagocytosis of microorganisms and degranulationmediated release of reactive oxygen species and antimicrobial peptides (FIG. 3c) . In addition, neutrophils release neutrophil extracellular traps (NETs) 92 , which contain DNA, histones, proteases and antimicro bial proteins. NET production is evident in the lungs of virusinfected mice 93 , and is associated with optimal clearance of bacterial infections during septicaemia 92 and fungal infections in lung tissue 94 . However, the toxic substances released by neutrophils can lead to irrepara ble damage and even host death. Therefore, stringent regulation of neutrophil responses is essential to prevent lifethreatening immunopathology. Effector responses in type 2 immunity. Type 2 effector immune responses can be mediated in either a single tiered or a twotiered manner. As discussed above, resi dent mast cells can execute a singletiered response by secreting mediators that directly act on local effectors to induce parasite expulsion (FIG. 4a) . In the context of a twotiered immune response, secondorder cytokine sig nals from innatelike lymphocytes initiate and amplify effector responses from AECs, basophils, eosino phils and macrophages in a coordinated effort to expel parasitic worms and repair damaged tissues (FIG. 4b) .
In addition to their roles as primary sensors of infec tion, AECs mediate effector functions that contrib ute to the resolution of disease (FIG. 4b) . Secondorder cytokines secreted by lymphoid cells promote type 2 effector responses, including airway cell replication and remodelling. IL13 signalling in AECs has several effects; it induces the production of CCL11 by mouse alveolar and bronchial epithelial cells 95 and enhances mucus pro duction by bronchial cells 96 . Repair of the airway epithe lium is important for effective resolution of antihelminth responses, and ILC2s have a central role in this process by producing IL5, IL13 and AREG, which promote epithelial regrowth 47, 68, 97 . Eosinophils are mostly absent from the lung in the steady state, and are recruited in response to IL5 derived from ILC2s, T H 2 cells and NKT cells, and CCL11 derived from AECs 98 (FIG. 4b) . Human eosinophils express the TSLP receptor, and TSLP signalling enhances their chemotaxis and survival, supporting eosinophil responses in the face of sustained tissue damage 99 . Eosinophils can thus be recruited in response to signals derived from either sensor cells or lymphoid cells, and once recruited they are responsive to additional signals produced by local sensors; these local signals function as a checkpoint to minimize prolonged eosinophil acti vation. Eosinophil degranulation results in the release of compounds that are toxic to helminths, including major basic protein and eosinophil cationic protein, as well as additional release of IL4 (REF. 100 ), which induces and enhances T H 2 cell and B cell responses to infection.
Basophils are recruited to the airways during allergen exposure and helminth infections. When they reach the lung they produce IL4 and interact with local memory T cells to enhance T H 2 cellmediated production of IL5 and IL13, and thereby potentiate airway inflamma tion 101, 102 (FIG. 4b) . In addition, basophils can be stimu lated by the firstorder cytokines IL33 and TSLP directly and by IgE 103 . Both human and mouse basophils prolif erate and increase their expression of cytokine receptors, including the IL33 receptor ST2 (also known IL1RL1), in response to TSLP 104 . IL33 signalling enhances basophil cytokine production and consequent airway inflammation 73, 102 , and thereby provides a direct path way for damaged AECs to induce basophil responses. T cellderived IL3 can also promote basophil activation and proliferation, but even in the absence of IL3 signal ling TSLP is sufficient to activate basophils directly 104, 105 . Basophils have a protective role in the context of recur rent Nippostrongylus brasiliensis infections in mice 106 , and basophilderived IL4 can also act on ILC2s, enhancing their production of IL9, IL13 and CCL11 to increase mast cell recruitment, eosinophilia and inflammation 102 . Mast cellderived chymase has a role in the degrada tion of alarmins, including IL33, in vivo in mice 107 and enables the rapid termination of type 2 responses. In addition, mast cells can constrain airway inflammation in response to papain in mice owing to their ability to produce IL2 and enhance regulatory T (T reg ) cell prolif eration 108 . Interestingly, mast cellderived proteases can also cleave IL33 into more potent forms to enhance ILC2 activation 109 , and whether these cells amplify or constrain the magnitude of the immune response is probably context dependent. Thus, both effector cytokines and effector cell types can amplify the immune response as needed, but they can also initiate negative feedback mechanisms that help to terminate immune responses when they are no longer required. 
Disease tolerance in the airway
Disease tolerance is an important host defence pathway that focuses on improving the ability of the host to tol erate tissue damage and is independent from the resist ance mechanisms that target pathogen elimination 110 . This concept is distinct from the classical immunologi cal paradigms of central and peripheral immunological tolerance. Disease tolerance is an essential strategy for surviving respiratory infections, and the mechanisms by which it is mediated are only just beginning to be understood. Aside from strengthening antimicrobial host defences, enhancing disease tolerance represents an important alternative strategy for future therapeutic interventions.
The mechanisms of disease tolerance are not well understood, but recent studies highlight emerging princi ples. ILC2s restore airway epithelial integrity after severe influenza A virus (IAV) infection via AREG secretion without altering viral load 97 (FIG. 4b) . Administering AREG to mice with a lethal IAV-bacterial coinfection can promote host survival without affecting pathogen burden 111 , which demonstrates that host resistance to infection and host survival can be uncoupled by tolerance mechanisms. IL22 is similarly protective against IAV associated epithelial cell death and damage, and does not alter viral burden both in vitro and in vivo 54, 57 (FIG. 3c) .
Tissue repair responses are not the only pathway to disease tolerance. For example, reducing the magni tude of inflammatory responses can improve survival without compromising antimicrobial host defence. In mice lacking the TLR and RLR signalling machinery necessary for IAV detection, disrupted activation of caspase 1 and caspase 11 can reverse IAVassociated lung tissue damage and mortality without altering patho gen burden 93 . Caspase 1 is also deleterious during the later stages of pneumonic plague without promoting bacterial clearance 112 , and it is responsible for causing CD4 + T cell loss in HIV1 infection without affecting viral load 113 . In mice, disease tolerance against IAV is also bolstered by glucose consumption during infec tion through a mechanism involving prevention of cell death downstream of IFN signalling in the hind brain 114 . Future identification of other mechanisms of disease tolerance is needed to inform the design of novel antiinflammatory agents.
Modifiers of respiratory immunity
The stepwise engagement of the immune response is the template for respiratory immunity, but many internal and external factors can disrupt this otherwise ordered process (FIG. 5) . Environmental and metabolic factors, as well as the ageing process, can change the way that the cells in the airways are activated or respond to stimuli, and the effects of these factors are often deleterious. The IFN response is particularly susceptible to many such influences and, given its important effector and regu latory roles in respiratory immunity, disruption of the IFN response probably has substantial consequences, although these are not yet fully understood. For exam ple, asthma is associated with a diminished IFN response to rhinovirus infection, but the precise relationship between this finding and disease pathogenesis is not yet known
External factors that alter respiratory immune responses.
The mucosal surface of the respiratory epi thelium is exposed to the external environment with every breath, and humans take approximately 20 breaths each minute. Therefore, the characteristics of the inhaled air, including its temperature, can potentially affect the biology of the surface epithelium. Changing the ambient temperature of AECs strongly influences their antiviral defence responses 115, 116 . Rhinovirus, which causes the common cold, is known to replicate more robustly at nasal cavity temperatures of 33-35 °C 115 . However, other doublestranded RNAdependent defence responses, including apoptosis and ribonuclease L activity, can con trol rhinovirus replication in human bronchial epithelial cells, and these responses are also diminished at nasal cavity temperature compared with at body tempera ture 116 . These findings suggest that the cool temperatures in the nasal cavity -which is further cooled when the inhaled air temperature is low -create a niche in which rhinovirus, and perhaps other respiratory viruses, can evade natural antiviral defence mechanisms.
In addition to temperature, evidence indicates that inhaled pollutants influence innate immune responses to viral infection of the airway, and many studies have
Box 2 | Asthma and the impaired respiratory innate defence
Asthma is a chronic lung disease that affects approximately 10% of the population and is most often characterized by asymptomatic periods punctuated with episodes of wheezing and respiratory distress. During the past decade, nucleic-acid-based virus detection methods have demonstrated that the most common trigger for these disease exacerbations is infection with a respiratory virus, most frequently with rhinoviruses; approximately 90% of childhood asthma attacks are virus related 140 . Early work on bronchial epithelial cells demonstrated a defect in rhinovirus-triggered induction of both type I and type III interferons (IFNs) in cells from patients with asthma compared with those from healthy controls 141, 142 . Subsequent studies have mostly corroborated these findings but have had mixed results [143] [144] [145] . Although this is an area of active investigation, it remains unclear which exact molecular mechanism accounts for the IFN defect in patients with asthma and whether this defect is a cause or an effect of asthma pathogenesis. Nevertheless, the observation that epithelial IFN responses are diminished in patients with asthma is intriguing, as it could potentially explain why rhinovirus infections have severe respiratory consequences in these patients but not in healthy individuals. Recent work suggests that the bacterial microbiota may also affect respiratory antiviral defence and asthma pathogenesis. As part of a longitudinal study of children at risk for asthma, investigators could retrospectively examine the early-life microbiota of children who subsequently developed asthma. This study revealed links between the presence of certain bacteria in the nasopharynx during viral respiratory infection in infancy, febrile respiratory infection in infancy and the subsequent development of asthma 146 . Together, these studies suggest that aberrant immune responses during respiratory virus infection may lie at the heart of asthma pathogenesis.
Metabolic syndrome
A set of risk factors -including obesity, elevated blood pressure and insulin resistance -that are associated with an increased risk of heart disease, diabetes and other negative clinical outcomes.
focused specifically on the effects of cigarette smoke. In a study of nasal epithelial cells from human smokers, the IFN response to IAV was dampened, and this correlated with diminished expression of the IFNinducing tran scription factor IRF7 and hypermethylation of the IRF7 promoter 117 . In vitro studies of AECs have also shown that exposure to chemicals from cigarette smoke dimin ishes the levels of IRF7 and other key signalling mol ecules that mediate IFN responses 118 . These effects may partially underlie the enhanced susceptibility of smokers to viral respiratory infections. A recent study in mice also suggests a possible role for IL33 in the exacerba tion of respiratory viral infection in smokers. Exposure of mice to cigarette smoke led to the increased expres sion of IL33 in bronchial and alveolar epithelial cells, and increased expression of ST2 on macrophages and NK cells, thereby 'setting the stage' for an exaggerated inflammatory response following a viral challenge 119 . These findings highlight how environmental factors can alter the regulation of the tiered structure of the respiratory immune response to pathological effect.
Impact of ageing on lung immunity. The ageing process has a wide range of disruptive effects on both adaptive and innate immunity, and older adults (over the age of 65) are more susceptible than younger adults to res piratory pathogens, which account for approximately 90% of the mortality associated with influenza virus infection and pneumonia in the United States each year 3 . Older individuals exhibit marked changes in lung physiology, including reduced respiratory muscle func tionality and impaired mucociliary clearance, which reduce the ability of the host to eliminate pathogens from the airway 120 (FIG. 5) . Ageing also has broad effects on innate immunity; compared with younger individu als, older individuals exhibit impairments in signalling through many TLRs and a skewing in haemato poiesis that favours myeloid cells 121 . However, ageing is also generally associated with increased baseline levels of inflammation 120 . In aged mice, increased prostaglandin D 2 expression in the lung suppresses DC migration to the draining lymph nodes, which leads to impaired development of an effective immune response 122 . Lung NK cell cytotoxi city and IFNγ secretion are decreased in mouse models of ageing and influenza virus infection 123 . Upon LPS stimu lation, aged mice exhibit increased pulmonary levels of CXCchemokine ligand 1 (CXCL1) and CXCL2, and increased neutrophil infiltration, which may be linked to increased IL1β production 124 . In addition, ageing impairs the ability of human peripheral blood monocytes to produce IFNs upon IAV infection or RIGI stimula tion 93 , and thereby impairs host resistance mechanisms within these cells. The combination of impaired antiviral resistance (due to IFN defects) with enhanced inflam masome responses and neutrophil activation results in lethal consequences following IAV infection 93, 125 . Impact of metabolic disease on lung immunity. Metabolic syndrome increases the risk for respiratory diseases; morbidly obese humans are more likely to require hos pitalization 2 and have an increased risk of developing asthma after IAV infection 126 (FIG. 5) . In general, obesity is associated with increased numbers of inflammatory M1 macrophages and CD8 + T cells, and decreased num bers of antiinflammatory M2 macrophages and T reg cells. Furthermore, in mice, a highfat diet is associated with increased numbers of monocytes and CD3 + lymphocytes in the lungs, even in the absence of infection 127 . Mice on a highfat diet exhibit increased airway hyperreactivity owing to an expansion of ILC3like cells that produce IL17A in the lung in response to IL1βreleased from M1 macrophages 128 . Mice with obesity show a reduced ability to control bacterial pneumonia 129 , and their impaired antimicrobial host defences may be a conse quence of reduced neutrophil recruitment into the alve oli; this recruitment is also reduced during airway injury and LPS challenge in obese mice 127 . Interestingly, during mouse H1N1 IAV infections, obesity is associated with increased lung pathology and impaired tissue repair without altered viral titres, suggesting that disease toler ance may also be compromised in obese individuals 130 . The TLRinduced IFN responses of peripheral blood cells from obese humans are impaired to a similar degree as those in cells from older individuals 131 , and this impair ment may have similarly broad implications for the loss of antiviral resistance and feedback regulation of respira tory immunity. Metabolic syndrome thus alters the fre quency and responsiveness of respiratory cell popu lations and disease tolerance mechanisms; it thereby disrupts the normal tiered structure of the immune response and increases the risk of infectionrelated immunopathology by reducing pathogen control.
Box 3 | Early responses to lung metastases
How the immune system recognizes and responds to metastatic cancer cells that migrate to the lung is an active area of investigation. Cytotoxic natural killer (NK) cells and CD8 + T cells are important for tumour lysis and elimination, and the mechanisms that mediate these responses against tumour cells in the lung are not fully understood. In mice, circulating tumour cells that arrive in the lung are first engulfed by neutrophils, monocytes, and non-alveolar macrophages and/or dendritic cells (DCs) in the lung vasculature in a stepwise fashion 147 . CC-chemokine ligand 2 (CCL2)-driven monocyte recruitment is important for tumour cell establishment and survival in the lung, in part due to the production of vascular endothelial growth factor (VEGF), which supports the endothelial extravasation of tumour cells 148 . Neutrophils similarly enable tumour cell extravasation and survival through the production of both interleukin-1β (IL-1β) and matrix metalloproteinase 9 (MMP9) 149, 150 , which act on the endothelium and alter the local microenvironment in a manner that ultimately supports tumour cell proliferation 149 . Neutrophils may also suppress systemic and local NK cell activation, further enabling the survival of circulating tumour cells 149 . In contrast to monocytes and neutrophils, lung-resident CD103 + DCs are important for the development of an effective antitumour immune response. Within 72 hours of tumour cell injection, CD103 + DCs phagocytose tumour cells and migrate to the mesenteric lymph nodes, which enhances T cell proliferation 147 . Alveolar macrophages suppress the proliferation and maturation of lung DCs and the subsequent T cell response in part through secretion of transforming growth factor-β; this suppressive effect of alveolar macrophages aims to maintain lung homeostasis in the absence of the activation of pattern recognition receptors and thereby enables metastatic proliferation 151 . Thus, a plausible model of the role of immune cells in lung metastasis is that local and recruited myeloid cells attempt to maintain a homeostatic state in the lung tissue as they do not detect any pathogen-associated signals, and in doing so they suppress the development of an otherwise effective antitumour immune response.
Concluding remarks
Specialized defence mechanisms are in place to protect the respiratory system against infections while minimiz ing tissue damage. Pathogens that manage to penetrate the mucus layer and enter AECs trigger cellintrinsic defences and the release of firstorder cytokines that inform tissueresident lymphocytes of the infection. In addition, resident macrophages, DCs and mast cells func tion as the primary sensors of incoming pathogens that breach the epithelial barrier. Various innate and memory lymphocytes resident in the tissue respond to the com bination of firstorder cytokines by producing second order cytokines that, in turn, act on effector cells, which eliminate pathogens and noxious substances. Although these responses are optimized for immune defence in the lungs, various external and internal factors -including ambient temperature, pollutants, ageing and obesitycan alter the efficiency with which the tiers of defence are engaged. In addition, the highly regulated nature of the respiratory immune system may be conducive to tumour metastasis and growth
There are still many unanswered questions relating to early immune responses in the lung. For example, what are the molecular pathways that enforce disease toler ance? Can we leverage such knowledge to treat acute and chronic inflammatory diseases? Another area of interest is to determine the functional consequences of triggering the activation of iNKT cells or T RM cells using cytokines versus specific antigens. In addition to the magnitude of response, are there fundamentally different immuno logi cal outcomes when stimulating these lymphocytes with firstorder cytokines versus antigens? Further areas of research might investigate whether prior exposure to a given pathogen or allergen dictates future responses to unrelated antigens. For instance, does exposure to virus 'X' establish a certain tissueresident lymphoid cell com position, and if so, does subsequent challenge by allergen or bacteria induce distinct outcomes? Can this explain the susceptibility of individuals to coinfections or asthma?
Finally, both ageing and obesity increase human sus ceptibility to a range of airway infections, by impairing host resistance mechanisms and/or by impairing disease tolerance. Reducing pathological inflammation in age ing and obese populations may provide an alternative means of limiting morbidity and mortality from infec tious diseases. Thus, understanding how the engagement of tiered immune responses integrates with disease toler ance mechanisms, and how ageing and obesity alter this underlying tiered structure, will offer further insights and inform better treatment of respiratory diseases.
